Submit Content
Get the latest delivered to your inbox
Privacy Policy

Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    Alkermes Releases Third Annual Corporate Responsibility Report Image

    POSTED 

    07-29-20

    Alkermes Releases Third Annual Corporate Responsibility Report

    Alkermes plc (Nasdaq: ALKS) today released its third annual Corporate Responsibility Report.  The report highlights the company’s corporate and social responsibility and environmental sustainability efforts, including recognition of the importance of continuing to increase the sophistication of moni...
    Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠  Program and 2019 Recipients Image

    POSTED 

    06-29-20

    Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠  Program and 2019 Recipients

    Alkermes plc (Nasdaq: ALKS) today announced that applications are now being accepted for the annual ALKERMES PATHWAYS RESEARCH AWARDSSM. The competitive grants program is designed to support the next generation of researchers working on the front lines to advance understanding and awareness of centr...
    Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities Image

    POSTED 

    06-24-20

    Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities

    Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonprofit organizations in their work to rap...
    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes Image

    POSTED 

    05-07-20

    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes

    In 2018, we significantly enhanced CaRE™, our proprietary risk mitigation program designed to encourage employees to preemptively identify and address EHSS risks and enhance sustainability.
    Statement from Alkermes on Response to COVID-19 Image

    POSTED 

    05-04-20

    Statement from Alkermes on Response to COVID-19

    Originally posted by Alkermes

    At Alkermes, we are closely monitoring and rapidly responding to the impact of COVID-19 on our employees...

    Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities Image

    POSTED 

    05-04-20

    Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities

     Alkermes plc (Nasdaq: ALKS) today announced that the company is now accepting applications for its newly-established COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program. The...

    Alkermes logo

    Alkermes

    Alkermes

    Join today and get the latest delivered to your inbox